Surolan is an FDA-approved prescription product that is the treatment of first choice for canine otitis externa associated with yeast and/or bacteria susceptible to miconazole and polymyxin B. With no known resistance issues, Surolan is ideally suited for new cases or cases unresponsive to previous treatments.
It is a non-aqueous suspension of: Miconazole nitrate as the antifungal, Polymyxin B sulphate as the anti-bacterial, Prednisolone acetate as the anti-inflammatory and antipruriticAdd this item to your cart:
**Note: This product requires a veterinarian's prescription to purchase.At checkout you will need to provide your veterinarian's FAX or email address. We will then send him or her a prescription verification that he or she will need to sign and return before we can ship you this product.
SUROLAN is indicated for the treatment of canine otitis externa associated with susceptible strains of yeast Malassezia pachydermatis and bacteria Staphylococcus pseudintermedius.
DOSAGE AND ADMINISTRATION:
Follow your Veterinarian prescription instructions for your pet. Shake well before use. The external ear should be thoroughly cleaned and dried before the initiation of treatment. Verify that the eardrum is intact. Instill 5 drops of SUROLAN in the ear canal twice daily and massage the ear. Therapy should continue for 7 consecutive days.
SUROLAN is contraindicated in dogs with suspected or known hypersensitivity to miconazole nitrate, polymyxin B sulfate, or prednisolone acetate. Do not use in dogs with known perforated tympanum. Do not use with drugs known to induce ototoxicity.
Not for use in humans. Keep this and all drugs out of reach of children.
Do not administer orally. For otic use only.
Before instilling any medication into the ear, examine the external ear canal thoroughly to be certain the tympanic membranes are not ruptured. If overgrowth of non-susceptible bacteria or fungi occurs, treatment should be discontinued and appropriate therapy instituted. Long-term use of topical otic corticosteroids has been associated with adrenocortical suppression and iatrogenic hypoadrenalcorticism in dogs. The safe use of SUROLAN in dogs used for breeding purposes, during pregnancy, or in lactating bitches, has not been evaluated.
In the field study, 161 dogs treated with SUROLAN were included in the safety database. Two dogs experienced reduced hearing at the end of treatment on follow-up one dog had normal hearing capacity while the other case was lost for follow-up. The owner of another dog reported that on day 4 of treatment, build-up of the medication decreased the dog's hearing. At the end of treatment, this dog had normal hearing as assessed by the investigator. Residue build-up was reported in 1 dog and pain upon drug application in another dog. A total of 161 dogs treated with the active control was included in the safety database and adverse reactions were reported in 8 dogs treated with the active control. One dog experienced reduced hearing at the end of treatment. Residue build-up was noted in 1 dog. Four dogs vomited during treatment, 1 dog showed red pustules on the pinna and head shaking was observed in another dog. Foreign market experience: the following adverse events were reported voluntarily during post-approval use of the product in foreign markets: deafness, reduced hearing, topical hypersensitivity reactions and red blisters on pinna.